Just listened to the briefing and Q+A. Feeling quite positive after listening because:
1) Cashflow positive, no debt.
2) Growing market and growing pipeline of products including USCOM and Ventitest
3) So it's likely that the current cashflow positive position will hold and expand in 2021
4) With revenue of over 4M in FY2020 , and MC of only 31M, the current share price is undervalued
One thing that I have tried to gauge, and which I haven't got an answer to, is regarding spironsonic. It appears to be a great tool with great relevance to COVID, remote monitoring and telehealth, but I still don't understand how it's different to the traditional spirometer. In another words, what is the competitive edge, and why would anyone choose to use spirosonic as opposed to the current iterations of spirometers? Hoping anyone with insight to help answer this question. Alternatively, does anyone have Rob's email address so I can ask this question directly to him?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.861M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250000 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 42000 | 1 |
View Market Depth
| Last trade - 16.21pm 25/07/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable